HSG Research

Huntington Study Group Data & Findings

Site Survey: Patients Supported by HD Centers (2019)

During March 2019, the HSG surveyed their 86 United States based sites (HD Centers), with 63 responding to reveal an average of 135 HD patients per center. Thus:

  • A total of 11,633 HD patients are estimated to be served by the HSG’s 86 US locations.
  • If the numerator is the number of patients seeking care (11,633 in the United States) and the denominator is the approximately 30,000 patients in the US with symptomatic HD (based on the literature), then it appears that there are 70% of people with HD who evade care.

 

Huntington Study Group Research

From PubMed.Gov

HSG’s 600+ investigators and coordinators publish research papers from the HD trials and studies they do with us. Below is an interactive list of publications from the trials and studies, as well as publications from the data from the trials and studies. Click on the hyperlink to access abstracts and papers.

Note: Some papers require a paid subscription to view.

  1. Anderson, KE, Griffin, J, Kinel, A, Shaikh, AR, Olofintuyi, T, Ramirez, S et al.. Quality of Care for Huntington's Disease in the United States: Findings from a National Survey of Patients and Caregivers. J Huntingtons Dis. 2019;8 (4):509-519. doi: 10.3233/JHD-190380. PubMed PMID:31594241 .
  2. Kayson, E, Eberly, S, Anderson, KE, Marder, K, Shoulson, I, Oakes, D et al.. The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation. J Huntingtons Dis. 2019;8 (4):435-441. doi: 10.3233/JHD-190365. PubMed PMID:31381523 .
  3. Li, F, Li, K, Li, C, Luo, S, PREDICT-HD and ENROLL-HD Investigators of the Huntington Study Group. Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers. J Huntingtons Dis. 2019;8 (3):323-332. doi: 10.3233/JHD-190345. PubMed PMID:31256145 PubMed Central PMC6718328.
  4. Shoulson, I, Eberly, S, Oakes, D, Kayson, E, Young, AB, PHAROS Investigators et al.. Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study. Ann Clin Transl Neurol. 2019;6 (6):1046-1052. doi: 10.1002/acn3.781. PubMed PMID:31211168 PubMed Central PMC6562068.
  5. Armstrong, MJ, Rastgardani, T, Gagliardi, AR, Marras, C. Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews. PLoS ONE. 2019;14 (4):e0215384. doi: 10.1371/journal.pone.0215384. PubMed PMID:30998707 PubMed Central PMC6472878.
  6. Ciarochi, JA, Johnson, HJ, Calhoun, VD, Liu, J, Espinoza, FA, Bockholt, HJ et al.. Concurrent Cross-Sectional and Longitudinal Analyses of Multivariate White Matter Profiles and Clinical Functioning in Pre-Diagnosis Huntington Disease. J Huntingtons Dis. 2019;8 (2):199-219. doi: 10.3233/JHD-180332. PubMed PMID:30932891 .
  7. McGarry, A, McDermott, MP, Kieburtz, K, Fung, WLA, McCusker, E, Peng, J et al.. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology. 2019;92 (14):e1643-e1651. doi: 10.1212/WNL.0000000000007244. PubMed PMID:30850442 PubMed Central PMC6448454.
  8. Braisch, U, Muche, R, Rothenbacher, D, Landwehrmeyer, GB, Long, JD, Orth, M et al.. Identification of symbol digit modality test score extremes in Huntington's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2019;180 (3):232-245. doi: 10.1002/ajmg.b.32719. PubMed PMID:30788902 .
  9. Reilmann, R, McGarry, A, Grachev, ID, Savola, JM, Borowsky, B, Eyal, E et al.. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18 (2):165-176. doi: 10.1016/S1474-4422(18)30391-0. PubMed PMID:30563778 .
  10. Ciarochi, JA, Liu, J, Calhoun, V, Johnson, H, Misiura, M, Bockholt, HJ et al.. High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease. Brain Sci. 2018;8 (7):. doi: 10.3390/brainsci8070116. PubMed PMID:29932126 PubMed Central PMC6071032.
  11. Liu, J, Ciarochi, J, Calhoun, VD, Paulsen, JS, Bockholt, HJ, Johnson, HJ et al.. Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease. Front Neurol. 2018;9 :190. doi: 10.3389/fneur.2018.00190. PubMed PMID:29651271 PubMed Central PMC5884935.
  12. Tanner, C, Marder, K, Eberly, S, Biglan, K, Oakes, D, Shoulson, I et al.. Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease. Mov. Disord. 2018;33 (3):472-478. doi: 10.1002/mds.27239. PubMed PMID:29297592 PubMed Central PMC5986294.
  13. Schobel, SA, Palermo, G, Auinger, P, Long, JD, Ma, S, Khwaja, OS et al.. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89 (24):2495-2502. doi: 10.1212/WNL.0000000000004743. PubMed PMID:29142089 PubMed Central PMC5729794.
  14. Anon. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group. Mov. Disord. 2017;32 (9):e1-e19. doi: 10.1002/mds.27134. PubMed PMID:28887904 .
  15. Hersch, SM, Schifitto, G, Oakes, D, Bredlau, AL, Meyers, CM, Nahin, R et al.. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology. 2017;89 (6):594-601. doi: 10.1212/WNL.0000000000004209. PubMed PMID:28701493 PubMed Central PMC5562960.
  16. Frank, S, Stamler, D, Kayson, E, Claassen, DO, Colcher, A, Davis, C et al.. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017;74 (8):977-982. doi: 10.1001/jamaneurol.2017.1352. PubMed PMID:28692723 PubMed Central PMC5710322.
  17. Wu, D, Faria, AV, Younes, L, Mori, S, Brown, T, Johnson, H et al.. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease. Hum Brain Mapp. 2017;38 (10):5035-5050. doi: 10.1002/hbm.23713. PubMed PMID:28657159 PubMed Central PMC5766002.
  18. Li, K, Furr-Stimming, E, Paulsen, JS, Luo, S, PREDICT-HD Investigators of the Huntington Study Group. Dynamic Prediction of Motor Diagnosis in Huntington's Disease Using a Joint Modeling Approach. J Huntingtons Dis. 2017;6 (2):127-137. doi: 10.3233/JHD-170236. PubMed PMID:28582868 PubMed Central PMC5505650.
  19. Westervelt, HJ, Bernier, RA, Faust, M, Gover, M, Bockholt, HJ, Zschiegner, R et al.. Data quality assurance and control in cognitive research: Lessons learned from the PREDICT-HD study. Int J Methods Psychiatr Res. 2017;26 (3):. doi: 10.1002/mpr.1534. PubMed PMID:28211597 PubMed Central PMC6258197.
  20. Anon. Abstracts from HSG 2016: Discovering Our Future, the 23rd Annual Meeting of the Huntington Study Group (HSG). Neurotherapeutics. 2017;14 (1):227-251. doi: 10.1007/s13311-016-0482-y. PubMed PMID:28083811 PubMed Central PMC5233626.
  21. Downing, NR, Lourens, S, De Soriano, I, Long, JD, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD. J Huntingtons Dis. 2016;5 (4):357-368. doi: 10.3233/JHD-160185. PubMed PMID:27983559 PubMed Central PMC6258187.
  22. McGarry, A, McDermott, M, Kieburtz, K, de Blieck, EA, Beal, F, Marder, K et al.. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88 (2):152-159. doi: 10.1212/WNL.0000000000003478. PubMed PMID:27913695 PubMed Central PMC5224719.
  23. Braisch, U, Hay, B, Muche, R, Rothenbacher, D, Landwehrmeyer, GB, Long, JD et al.. Identification of extreme motor phenotypes in Huntington's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2017;174 (3):283-294. doi: 10.1002/ajmg.b.32514. PubMed PMID:27868347 .
  24. Quaid, KA, Eberly, SW, Kayson-Rubin, E, Oakes, D, Shoulson, I, Huntington Study Group PHAROS Investigators and Coordinators et al.. Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS). Clin. Genet. 2017;91 (6):824-831. doi: 10.1111/cge.12893. PubMed PMID:27740685 PubMed Central PMC5392180.
  25. Ciarochi, JA, Calhoun, VD, Lourens, S, Long, JD, Johnson, HJ, Bockholt, HJ et al.. Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease Prodrome. Front Neurol. 2016;7 :147. doi: 10.3389/fneur.2016.00147. PubMed PMID:27708610 PubMed Central PMC5030293.
  26. Salem, L, Saleh, N, Désaméricq, G, Youssov, K, Dolbeau, G, Cleret, L et al.. Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease. PLoS ONE. 2016;11 (9):e0162890. doi: 10.1371/journal.pone.0162890. PubMed PMID:27627435 PubMed Central PMC5023180.
  27. Harrington, DL, Long, JD, Durgerian, S, Mourany, L, Koenig, K, Bonner-Jackson, A et al.. Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease. Mov. Disord. 2016;31 (11):1664-1675. doi: 10.1002/mds.26803. PubMed PMID:27620011 PubMed Central PMC5115975.
  28. Huntington Study Group, Frank, S, Testa, CM, Stamler, D, Kayson, E, Davis, C et al.. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016;316 (1):40-50. doi: 10.1001/jama.2016.8655. PubMed PMID:27380342 .
  29. Faria, AV, Ratnanather, JT, Tward, DJ, Lee, DS, van den Noort, F, Wu, D et al.. Linking white matter and deep gray matter alterations in premanifest Huntington disease. Neuroimage Clin. 2016;11 :450-460. doi: 10.1016/j.nicl.2016.02.014. PubMed PMID:27104139 PubMed Central PMC4827723.
  30. Carvalho, JO, Long, JD, Westervelt, HJ, Smith, MM, Bruce, JM, Kim, JI et al.. The impact of oculomotor functioning on neuropsychological performance in Huntington disease. J Clin Exp Neuropsychol. 2016;38 (2):217-26. doi: 10.1080/13803395.2015.1101054. PubMed PMID:26745770 .
  31. Huntington Study Group PHAROS Investigators, Biglan, KM, Shoulson, I, Kieburtz, K, Oakes, D, Kayson, E et al.. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016;73 (1):102-10. doi: 10.1001/jamaneurol.2015.2736. PubMed PMID:26569098 .
  32. Epping, EA, Kim, JI, Craufurd, D, Brashers-Krug, TM, Anderson, KE, McCusker, E et al.. Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data. Am J Psychiatry. 2016;173 (2):184-92. doi: 10.1176/appi.ajp.2015.14121551. PubMed PMID:26472629 PubMed Central PMC5465431.
  33. Liu, D, Long, JD, Zhang, Y, Raymond, LA, Marder, K, Rosser, A et al.. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J. Neurol. 2015;262 (12):2691-8. doi: 10.1007/s00415-015-7900-7. PubMed PMID:26410751 PubMed Central PMC4666501.
  34. Long, JD, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD. Mov. Disord. 2015;30 (12):1664-72. doi: 10.1002/mds.26364. PubMed PMID:26340420 PubMed Central PMC4795466.
  35. Musso, M, Westervelt, HJ, Long, JD, Morgan, E, Woods, SP, Smith, MM et al.. Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden. J Int Neuropsychol Soc. 2015;21 (1):8-21. doi: 10.1017/S1355617714001076. PubMed PMID:26304055 PubMed Central PMC4549971.
  36. Matsui, JT, Vaidya, JG, Wassermann, D, Kim, RE, Magnotta, VA, Johnson, HJ et al.. Prefrontal cortex white matter tracts in prodromal Huntington disease. Hum Brain Mapp. 2015;36 (10):3717-32. doi: 10.1002/hbm.22835. PubMed PMID:26179962 PubMed Central PMC4583330.
  37. Dorsey, ER, Darwin, KC, Mohammed, S, Donohue, S, Tethal, A, Achey, MA et al.. Virtual research visits and direct-to-consumer genetic testing in Parkinson's disease. Digit Health. ;1 :2055207615592998. doi: 10.1177/2055207615592998. PubMed PMID:29942542 PubMed Central PMC5999055.
  38. Harrington, DL, Rubinov, M, Durgerian, S, Mourany, L, Reece, C, Koenig, K et al.. Network topology and functional connectivity disturbances precede the onset of Huntington's disease. Brain. 2015;138 (Pt 8):2332-46. doi: 10.1093/brain/awv145. PubMed PMID:26059655 PubMed Central PMC5022662.
  39. Kim, JI, Long, JD, Mills, JA, McCusker, E, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease. Neuropsychology. 2015;29 (6):949-60. doi: 10.1037/neu0000199. PubMed PMID:26011117 PubMed Central PMC4640959.
  40. Kim, JI, Long, JD, Mills, JA, Downing, N, Williams, JK, Paulsen, JS et al.. Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease. Eur. J. Hum. Genet. 2015;23 (11):1584-7. doi: 10.1038/ejhg.2015.11. PubMed PMID:25735480 PubMed Central PMC4613468.
  41. Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14 (1):39-47. doi: 10.1016/S1474-4422(14)70262-5. PubMed PMID:25467848 .
  42. Paulsen, JS, Long, JD, Ross, CA, Harrington, DL, Erwin, CJ, Williams, JK et al.. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014;13 (12):1193-201. doi: 10.1016/S1474-4422(14)70238-8. PubMed PMID:25453459 PubMed Central PMC4373455.
  43. Koenig, KA, Lowe, MJ, Harrington, DL, Lin, J, Durgerian, S, Mourany, L et al.. Functional connectivity of primary motor cortex is dependent on genetic burden in prodromal Huntington disease. Brain Connect. 2014;4 (7):535-46. doi: 10.1089/brain.2014.0271. PubMed PMID:25072408 PubMed Central PMC4146393.
  44. Williams, JK, Kim, JI, Downing, N, Farias, S, Harrington, DL, Long, JD et al.. Everyday cognition in prodromal Huntington disease. Neuropsychology. 2015;29 (2):255-67. doi: 10.1037/neu0000102. PubMed PMID:25000321 PubMed Central PMC4286521.
  45. Paulsen, JS, Long, JD, Johnson, HJ, Aylward, EH, Ross, CA, Williams, JK et al.. Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Front Aging Neurosci. 2014;6 :78. doi: 10.3389/fnagi.2014.00078. PubMed PMID:24795630 PubMed Central PMC4000999.
  46. Georgiou-Karistianis, N, Long, JD, Lourens, SG, Stout, JC, Mills, JA, Paulsen, JS et al.. Movement sequencing in Huntington disease. World J. Biol. Psychiatry. 2014;15 (6):459-71. doi: 10.3109/15622975.2014.895042. PubMed PMID:24678867 PubMed Central PMC4389285.
  47. Nagel, M, Rumpf, HJ, Kasten, M. Acute psychosis in a verified Huntington disease gene carrier with subtle motor signs: psychiatric criteria should be considered for the diagnosis. Gen Hosp Psychiatry. ;36 (3):361.e3-4. doi: 10.1016/j.genhosppsych.2014.01.008. PubMed PMID:24576988 .
  48. Downing, NR, Kim, JI, Williams, JK, Long, JD, Mills, JA, Paulsen, JS et al.. WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease. Eur. J. Hum. Genet. 2014;22 (8):958-63. doi: 10.1038/ejhg.2013.275. PubMed PMID:24327189 PubMed Central PMC4350592.
  49. Dorsey, ER, Beck, CA, Darwin, K, Nichols, P, Brocht, AF, Biglan, KM et al.. Natural history of Huntington disease. JAMA Neurol. 2013;70 (12):1520-30. doi: 10.1001/jamaneurol.2013.4408. PubMed PMID:24126537 .
  50. Marder, K, Gu, Y, Eberly, S, Tanner, CM, Scarmeas, N, Oakes, D et al.. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013;70 (11):1382-8. doi: 10.1001/jamaneurol.2013.3487. PubMed PMID:24000094 PubMed Central PMC4040231.
  51. McCusker, EA, Gunn, DG, Epping, EA, Loy, CT, Radford, K, Griffith, J et al.. Unawareness of motor phenoconversion in Huntington disease. Neurology. 2013;81 (13):1141-7. doi: 10.1212/WNL.0b013e3182a55f05. PubMed PMID:23966256 PubMed Central PMC3795599.
  52. Moscovitch-Lopatin, M, Goodman, RE, Eberly, S, Ritch, JJ, Rosas, HD, Matson, S et al.. HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology. 2013;81 (13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. PubMed PMID:23966247 PubMed Central PMC3795598.
  53. Paulsen, JS, Smith, MM, Long, JD, PREDICT HD investigators and Coordinators of the Huntington Study Group. Cognitive decline in prodromal Huntington Disease: implications for clinical trials. J. Neurol. Neurosurg. Psychiatry. 2013;84 (11):1233-9. doi: 10.1136/jnnp-2013-305114. PubMed PMID:23911948 PubMed Central PMC3795884.
  54. Epping, EA, Mills, JA, Beglinger, LJ, Fiedorowicz, JG, Craufurd, D, Smith, MM et al.. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J Psychiatr Res. 2013;47 (10):1423-31. doi: 10.1016/j.jpsychires.2013.05.026. PubMed PMID:23790259 PubMed Central PMC3808084.
  55. Bonner-Jackson, A, Long, JD, Westervelt, H, Tremont, G, Aylward, E, Paulsen, JS et al.. Cognitive reserve and brain reserve in prodromal Huntington's disease. J Int Neuropsychol Soc. 2013;19 (7):739-50. doi: 10.1017/S1355617713000507. PubMed PMID:23702309 PubMed Central PMC3720793.
  56. Biglan, KM, Zhang, Y, Long, JD, Geschwind, M, Kang, GA, Killoran, A et al.. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci. 2013;5 :12. doi: 10.3389/fnagi.2013.00012. PubMed PMID:23565093 PubMed Central PMC3613616.
  57. Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov. Disord. 2013;28 (10):1407-15. doi: 10.1002/mds.25362. PubMed PMID:23450660 .
  58. Goh, AM, Chiu, E, Yastrubetskaya, O, Erwin, C, Williams, JK, Juhl, AR et al.. Perception, experience, and response to genetic discrimination in Huntington's disease: the Australian results of The International RESPOND-HD study. Genet Test Mol Biomarkers. 2013;17 (2):115-21. doi: 10.1089/gtmb.2012.0288. PubMed PMID:23289616 PubMed Central PMC3552166.
  59. Younes, L, Ratnanather, JT, Brown, T, Aylward, E, Nopoulos, P, Johnson, H et al.. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp. 2014;35 (3):792-809. doi: 10.1002/hbm.22214. PubMed PMID:23281100 PubMed Central PMC3715588.
  60. Aylward, EH, Harrington, DL, Mills, JA, Nopoulos, PC, Ross, CA, Long, JD et al.. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingtons Dis. 2013;2 (4):477-89. doi: 10.3233/JHD-130076. PubMed PMID:25062732 PubMed Central PMC4412155.
  61. HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol. 2013;70 (1):25-33. doi: 10.1001/2013.jamaneurol.382. PubMed PMID:23108692 .
  62. Cooper, SE, McIntyre, CC, Fernandez, HH, Vitek, JL. Association of deep brain stimulation washout effects with Parkinson disease duration. JAMA Neurol. 2013;70 (1):95-9. doi: 10.1001/jamaneurol.2013.581. PubMed PMID:23070397 PubMed Central PMC5148628.
  63. Brossman, B, Williams, JK, Downing, N, Mills, JA, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. Development of the Huntington disease work function scale. J. Occup. Environ. Med. 2012;54 (10):1300-8. doi: 10.1097/JOM.0b013e31825f30ab. PubMed PMID:22995807 PubMed Central PMC3466392.
  64. Smith, MM, Mills, JA, Epping, EA, Westervelt, HJ, Paulsen, JS, PREDICT-HD Investigators of the Huntington Study Group et al.. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology. 2012;26 (5):664-9. doi: 10.1037/a0029218. PubMed PMID:22846033 PubMed Central PMC3806339.
  65. Lee, JH, Lee, JM, Ramos, EM, Gillis, T, Mysore, JS, Kishikawa, S et al.. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem. Biophys. Res. Commun. 2012;424 (3):404-8. doi: 10.1016/j.bbrc.2012.06.120. PubMed PMID:22771793 PubMed Central PMC3752397.
  66. Harrington, DL, Smith, MM, Zhang, Y, Carlozzi, NE, Paulsen, JS, PREDICT-HD Investigators of the Huntington Study Group et al.. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry. 2012;83 (6):612-9. doi: 10.1136/jnnp-2011-301732. PubMed PMID:22451099 PubMed Central PMC3812822.
  67. Long, JD, Matson, WR, Juhl, AR, Leavitt, BR, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. 8OHdG as a marker for Huntington disease progression. Neurobiol. Dis. 2012;46 (3):625-34. doi: 10.1016/j.nbd.2012.02.012. PubMed PMID:22414782 PubMed Central PMC3784019.
  68. Rowe, KC, Paulsen, JS, Langbehn, DR, Wang, C, Mills, J, Beglinger, LJ et al.. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2012;196 (2-3):309-14. doi: 10.1016/j.psychres.2011.09.005. PubMed PMID:22397915 PubMed Central PMC3763706.
  69. Huntington Study Group COHORT Investigators, Dorsey, E. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS ONE. 2012;7 (2):e29522. doi: 10.1371/journal.pone.0029522. PubMed PMID:22359536 PubMed Central PMC3281013.
  70. Lee, JM, Ramos, EM, Lee, JH, Gillis, T, Mysore, JS, Hayden, MR et al.. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78 (10):690-5. doi: 10.1212/WNL.0b013e318249f683. PubMed PMID:22323755 PubMed Central PMC3306163.
  71. Anon. Fifth Annual Huntington Disease Clinical Research Symposium. Organized by the Huntington Study Group. Neurotherapeutics. 2012;9 (1):226-39. doi: 10.1007/s13311-011-0083-8. PubMed PMID:22302517 PubMed Central PMC4883046.
  72. Biglan, KM, Dorsey, ER, Evans, RV, Ross, CA, Hersch, S, Shoulson, I et al.. Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10. J Huntingtons Dis. 2012;1 (1):65-9. doi: 10.3233/JHD-2012-120007. PubMed PMID:25063191 PubMed Central PMC4115297.
  73. Aylward, EH, Liu, D, Nopoulos, PC, Ross, CA, Pierson, RK, Mills, JA et al.. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol. Psychiatry. 2012;71 (9):822-8. doi: 10.1016/j.biopsych.2011.07.030. PubMed PMID:21907324 PubMed Central PMC3237730.
  74. Zhang, Y, Long, JD, Mills, JA, Warner, JH, Lu, W, Paulsen, JS et al.. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011;156B (7):751-63. doi: 10.1002/ajmg.b.31232. PubMed PMID:21858921 PubMed Central PMC3174494.
  75. Carlozzi, NE, Stout, JC, Mills, JA, Duff, K, Beglinger, LJ, Aylward, EH et al.. Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease. Clin Neuropsychol. 2011;25 (5):757-77. doi: 10.1080/13854046.2011.577811. PubMed PMID:21660882 PubMed Central PMC3159182.
  76. Fiedorowicz, JG, Mills, JA, Ruggle, A, Langbehn, D, Paulsen, JS, PREDICT-HD Investigators of the Huntington Study Group et al.. Suicidal behavior in prodromal Huntington disease. Neurodegener Dis. 2011;8 (6):483-90. doi: 10.1159/000327754. PubMed PMID:21659725 PubMed Central PMC3186721.
  77. Downing, N, Smith, MM, Beglinger, LJ, Mills, J, Duff, K, Rowe, KC et al.. Perceived stress in prodromal Huntington disease. Psychol Health. 2012;27 (2):196-209. doi: 10.1080/08870446.2010.529141. PubMed PMID:21623544 PubMed Central PMC3165107.
  78. Wetzel, HH, Gehl, CR, Dellefave-Castillo, L, Schiffman, JF, Shannon, KM, Paulsen, JS et al.. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188 (3):372-6. doi: 10.1016/j.psychres.2011.05.006. PubMed PMID:21605914 PubMed Central PMC3790459.
  79. Goodman, L, Sia, C, Carnes, R, Vetter, L, Taubman, F, Venuto, CS et al.. Advocacy Recruiting for Huntington's Disease Clinical Trials. PLoS Curr. 2011;3 :RRN1230. doi: 10.1371/currents.RRN1230. PubMed PMID:21532913 PubMed Central PMC3082401.
  80. Nopoulos, PC, Aylward, EH, Ross, CA, Mills, JA, Langbehn, DR, Johnson, HJ et al.. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain. 2011;134 (Pt 1):137-42. doi: 10.1093/brain/awq280. PubMed PMID:20923788 PubMed Central PMC3025719.
  81. Aylward, EH, Nopoulos, PC, Ross, CA, Langbehn, DR, Pierson, RK, Mills, JA et al.. Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry. 2011;82 (4):405-10. doi: 10.1136/jnnp.2010.208264. PubMed PMID:20884680 PubMed Central PMC3105627.
  82. Quaid, KA, Swenson, MM, Sims, SL, Harrison, JM, Moskowitz, C, Stepanov, N et al.. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19 (6):606-17. doi: 10.1007/s10897-010-9312-2. PubMed PMID:20734119 PubMed Central PMC3686108.
  83. Williams, JK, Erwin, C, Juhl, A, Mills, J, Brossman, B, Paulsen, JS et al.. Personal factors associated with reported benefits of Huntington disease family history or genetic testing. Genet Test Mol Biomarkers. 2010;14 (5):629-36. doi: 10.1089/gtmb.2010.0065. PubMed PMID:20722493 PubMed Central PMC2957234.
  84. Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington's disease. Mov. Disord. 2010;25 (13):2219-24. doi: 10.1002/mds.23236. PubMed PMID:20721920 .
  85. Nopoulos, PC, Aylward, EH, Ross, CA, Johnson, HJ, Magnotta, VA, Juhl, AR et al.. Cerebral cortex structure in prodromal Huntington disease. Neurobiol. Dis. 2010;40 (3):544-54. doi: 10.1016/j.nbd.2010.07.014. PubMed PMID:20688164 PubMed Central PMC2955824.
  86. Soneson, C, Fontes, M, Zhou, Y, Denisov, V, Paulsen, JS, Kirik, D et al.. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 2010;40 (3):531-43. doi: 10.1016/j.nbd.2010.07.013. PubMed PMID:20682340 PubMed Central PMC2955781.
  87. Huntington Study Group Pre2CARE Investigators, Hyson, HC, Kieburtz, K, Shoulson, I, McDermott, M, Ravina, B et al.. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov. Disord. 2010;25 (12):1924-8. doi: 10.1002/mds.22408. PubMed PMID:20669312 .
  88. Paulsen, JS, Wang, C, Duff, K, Barker, R, Nance, M, Beglinger, L et al.. Challenges assessing clinical endpoints in early Huntington disease. Mov. Disord. 2010;25 (15):2595-603. doi: 10.1002/mds.23337. PubMed PMID:20623772 PubMed Central PMC2978744.
  89. Duff, K, Paulsen, J, Mills, J, Beglinger, LJ, Moser, DJ, Smith, MM et al.. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 2010;75 (6):500-7. doi: 10.1212/WNL.0b013e3181eccfa2. PubMed PMID:20610833 PubMed Central PMC2918475.
  90. Beglinger, LJ, O'Rourke, JJ, Wang, C, Langbehn, DR, Duff, K, Paulsen, JS et al.. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178 (2):414-8. doi: 10.1016/j.psychres.2010.04.030. PubMed PMID:20471695 PubMed Central PMC3629818.
  91. Williams, JK, Erwin, C, Juhl, AR, Mengeling, M, Bombard, Y, Hayden, MR et al.. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010;153B (6):1150-9. doi: 10.1002/ajmg.b.31080. PubMed PMID:20468062 PubMed Central PMC3035936.
  92. Erwin, C, Williams, JK, Juhl, AR, Mengeling, M, Mills, JA, Bombard, Y et al.. Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010;153B (5):1081-93. doi: 10.1002/ajmg.b.31079. PubMed PMID:20468061 PubMed Central PMC3593716.
  93. Duff, K, Paulsen, JS, Beglinger, LJ, Langbehn, DR, Wang, C, Stout, JC et al.. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci. 2010;22 (2):196-207. doi: 10.1176/jnp.2010.22.2.196. PubMed PMID:20463114 PubMed Central PMC2871328.
  94. Kieburtz, K, McDermott, MP, Voss, TS, Corey-Bloom, J, Deuel, LM, Dorsey, ER et al.. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch. Neurol. 2010;67 (2):154-60. doi: 10.1001/archneurol.2009.334. PubMed PMID:20142523 PubMed Central PMC4134015.
  95. Frank, S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9 :62. doi: 10.1186/1471-2377-9-62. PubMed PMID:20021666 PubMed Central PMC2804668.
  96. Marder, K, Zhao, H, Eberly, S, Tanner, CM, Oakes, D, Shoulson, I et al.. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009;73 (5):385-92. doi: 10.1212/WNL.0b013e3181b04aa2. PubMed PMID:19652143 PubMed Central PMC2725927.
  97. Biglan, KM, Ross, CA, Langbehn, DR, Aylward, EH, Stout, JC, Queller, S et al.. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov. Disord. 2009;24 (12):1763-72. doi: 10.1002/mds.22601. PubMed PMID:19562761 PubMed Central PMC3048804.
  98. Langbehn, DR, Hayden, MR, Paulsen, JS, and the PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010;153B (2):397-408. doi: 10.1002/ajmg.b.30992. PubMed PMID:19548255 PubMed Central PMC3048807.
  99. Klöppel, S, Chu, C, Tan, GC, Draganski, B, Johnson, H, Paulsen, JS et al.. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology. 2009;72 (5):426-31. doi: 10.1212/01.wnl.0000341768.28646.b6. PubMed PMID:19188573 PubMed Central PMC2817939.
  100. Dorsey, ER, Beck, CA, Adams, M, Chadwick, G, de Blieck, EA, McCallum, C et al.. Communicating clinical trial results to research participants. Arch. Neurol. 2008;65 (12):1590-5. doi: 10.1001/archneurol.2008.503. PubMed PMID:19064746 .
  101. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch. Neurol. 2008;65 (12):1582-9. doi: 10.1001/archneur.65.12.1582. PubMed PMID:19064745 .
  102. Oster, E, Dorsey, ER, Bausch, J, Shinaman, A, Kayson, E, Oakes, D et al.. Fear of health insurance loss among individuals at risk for Huntington disease. Am. J. Med. Genet. A. 2008;146A (16):2070-7. doi: 10.1002/ajmg.a.32422. PubMed PMID:18627059 PubMed Central PMC2574833.
  103. Paulsen, JS, Langbehn, DR, Stout, JC, Aylward, E, Ross, CA, Nance, M et al.. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry. 2008;79 (8):874-80. doi: 10.1136/jnnp.2007.128728. PubMed PMID:18096682 PubMed Central PMC2569211.
  104. Erwin, C, Hersch, S, Event Monitoring Committee of the Huntington Study Group. Monitoring reportable events and unanticipated problems: the PHAROS and PREDICT studies of Huntington disease. IRB. ;29 (3):11-6. . PubMed PMID:17847637 .
  105. Johnson, SA, Stout, JC, Solomon, AC, Langbehn, DR, Aylward, EH, Cruce, CB et al.. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain. 2007;130 (Pt 7):1732-44. doi: 10.1093/brain/awm107. PubMed PMID:17584778 .
  106. Langbehn, DR, Paulsen, JS, Huntington Study Group. Predictors of diagnosis in Huntington disease. Neurology. 2007;68 (20):1710-7. doi: 10.1212/01.wnl.0000261918.90053.96. PubMed PMID:17502553 .
  107. Duff, K, Paulsen, JS, Beglinger, LJ, Langbehn, DR, Stout, JC, Predict-HD Investigators of the Huntington Study Group et al.. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry. 2007;62 (12):1341-6. doi: 10.1016/j.biopsych.2006.11.034. PubMed PMID:17481592 .
  108. Solomon, AC, Stout, JC, Johnson, SA, Langbehn, DR, Aylward, EH, Brandt, J et al.. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 2007;45 (8):1767-76. doi: 10.1016/j.neuropsychologia.2006.12.015. PubMed PMID:17303196 PubMed Central PMC2570315.
  109. Beglinger, LJ, Langbehn, DR, Duff, K, Stierman, L, Black, DW, Nehl, C et al.. Probability of obsessive and compulsive symptoms in Huntington's disease. Biol. Psychiatry. 2007;61 (3):415-8. doi: 10.1016/j.biopsych.2006.04.034. PubMed PMID:16839521 .
  110. Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch. Neurol. 2006;63 (7):991-6. doi: 10.1001/archneur.63.7.991. PubMed PMID:16831969 .
  111. Paulsen, JS, Hayden, M, Stout, JC, Langbehn, DR, Aylward, E, Ross, CA et al.. Preparing for preventive clinical trials: the Predict-HD study. Arch. Neurol. 2006;63 (6):883-90. doi: 10.1001/archneur.63.6.883. PubMed PMID:16769871 .
  112. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66 (3):366-72. doi: 10.1212/01.wnl.0000198586.85250.13. PubMed PMID:16476934 .
  113. Paulsen, JS, Hoth, KF, Nehl, C, Stierman, L. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005;162 (4):725-31. doi: 10.1176/appi.ajp.162.4.725. PubMed PMID:15800145 .
  114. Tumas, V, Camargos, ST, Jalali, PS, Galesso, Ade P, Marques, W Jr. Internal consistency of a Brazilian version of the unified Huntington's disease rating scale. Arq Neuropsiquiatr. 2004;62 (4):977-82. doi: 10.1590/S0004-282X2004000600009. PubMed PMID:15608955 .
  115. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004;63 (3):547-9. doi: 10.1212/01.wnl.0000133403.30559.ff. PubMed PMID:15304592 .
  116. Hamilton, JM, Wolfson, T, Peavy, GM, Jacobson, MW, Corey-Bloom, J, Huntington Study Group et al.. Rate and correlates of weight change in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 2004;75 (2):209-12. doi: 10.1136/jnnp.2003.017822. PubMed PMID:14742590 PubMed Central PMC1738924.
  117. Nehl, C, Paulsen, JS, Huntington Study Group. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J. Nerv. Ment. Dis. 2004;192 (1):72-4. doi: 10.1097/01.nmd.0000106004.67587.57. PubMed PMID:14718780 .
  118. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology. 2003;61 (11):1551-6. doi: 10.1212/01.wnl.0000096019.71649.2b. PubMed PMID:14663041 .
  119. Mahant, N, McCusker, EA, Byth, K, Graham, S, Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61 (8):1085-92. doi: 10.1212/01.wnl.0000086373.32347.16. PubMed PMID:14581669 .
  120. Wheelock, VL, Tempkin, T, Marder, K, Nance, M, Myers, RH, Zhao, H et al.. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60 (6):998-1001. doi: 10.1212/01.wnl.0000052992.58107.67. PubMed PMID:12654967 .
  121. Djoussé, L, Knowlton, B, Cupples, LA, Marder, K, Shoulson, I, Myers, RH et al.. Weight loss in early stage of Huntington's disease. Neurology. 2002;59 (9):1325-30. doi: 10.1212/01.wnl.0000031791.10922.cf. PubMed PMID:12427878 .
  122. Paulsen, JS, Zhao, H, Stout, JC, Brinkman, RR, Guttman, M, Ross, CA et al.. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001;57 (4):658-62. doi: 10.1212/wnl.57.4.658. PubMed PMID:11524475 .
  123. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57 (3):397-404. doi: 10.1212/wnl.57.3.397. PubMed PMID:11502903 .
  124. Marder, K, Zhao, H, Myers, RH, Cudkowicz, M, Kayson, E, Kieburtz, K et al.. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000;54 (2):452-8. doi: 10.1212/wnl.54.2.452. PubMed PMID:10668713 .
  125. Anon. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group. Neurology. 1998;50 (5):1366-73. doi: 10.1212/wnl.50.5.1366. PubMed PMID:9595988 .
  126. Anon. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov. Disord. 1996;11 (2):136-42. doi: 10.1002/mds.870110204. PubMed PMID:8684382 .
Search PubMed